Orbit Discovery and Evergreen Discovery collaborate to discover peptides for targeting radiopharmaceuticals

 Evergreen Discovery (Evergreen), a leading radiopharmaceutical drug development company with a focus on the treatment and diagnosis of cancer, and Orbit Discovery Ltd (Orbit), a leader in the discovery of therapeutic peptide hits, announced today that they have entered into a collaboration to identify specific cell-targeting peptides and advance the development of novel radiopharmaceuticals. The agreement covers activities ranging from designing peptide libraries, hit identification, and hit validation to confirm cell surface binding properties.

The radiopharmaceuticals market is rapidly expanding with the development of a variety of targeting moieties. These moieties allow for specific binding to a tumor target of interest, thereby localizing the treatment to diseased tissues. Peptides are increasingly seen as a valuable delivery option, as their specificity, stability, and rapid clearance have the potential to reduce off-target toxicities.

The collaboration will leverage Orbit’s peptide display technologies to find peptide leads specific to tumour-related targets of interest. The proprietary platform will harness its unique ability to perform in vitro transcription-translation from DNA-encoded libraries on beads. This capability allows for the screening of huge libraries using Fluorescence-activated cell sorting (FACS)-based methodologies, thereby significantly increasing throughput above other competing technologies. Evergreen will focus on the subsequent development of the peptides for clinical use.

 “We are very pleased to be partnering with Orbit Discovery and capitalising on its technology and expertise in both chemistry and biology to drive innovation and expansion of our radiopharmaceutical candidate pipeline.” He added: “The requirement for more direct screening technologies is key to successful drug development and we see Orbit as a steppingstone in attaining our goals in a rapid timeframe.”

Dr Thomas Reiner, Chief Scientific Officer, Evergreen Discovery

 “Evergreen Discovery is a pioneer in the field of radiopharmaceuticals, and we’re delighted to be collaborating with the team. In conjunction with their capabilities in manufacturing, we aim to assist them in rapidly moving targeted radiopharmaceuticals into the clinic.” 

Dr Neil Butt, Chief Executive Officer, Orbit Discovery

He added, “This area of therapeutic drug development benefits significantly from our platform, where the higher numbers screened typically allow for better outputs and thereby reduce risk at a later stage in development.”

Orbit Discovery will be attending TIDES in San Diego, 7th -8th May and will be at the partnering event at BIO International in Boston June 5th – 8th 2023.

For further information, please visit: https://www.orbitdiscovery.com/

 

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Orbit Discovery. (2023, April 03). Orbit Discovery and Evergreen Discovery collaborate to discover peptides for targeting radiopharmaceuticals. News-Medical. Retrieved on July 15, 2024 from https://www.news-medical.net/news/20230403/Orbit-Discovery-and-Evergreen-Discovery-collaborate-to-discover-peptides-for-targeting-radiopharmaceuticals.aspx.

  • MLA

    Orbit Discovery. "Orbit Discovery and Evergreen Discovery collaborate to discover peptides for targeting radiopharmaceuticals". News-Medical. 15 July 2024. <https://www.news-medical.net/news/20230403/Orbit-Discovery-and-Evergreen-Discovery-collaborate-to-discover-peptides-for-targeting-radiopharmaceuticals.aspx>.

  • Chicago

    Orbit Discovery. "Orbit Discovery and Evergreen Discovery collaborate to discover peptides for targeting radiopharmaceuticals". News-Medical. https://www.news-medical.net/news/20230403/Orbit-Discovery-and-Evergreen-Discovery-collaborate-to-discover-peptides-for-targeting-radiopharmaceuticals.aspx. (accessed July 15, 2024).

  • Harvard

    Orbit Discovery. 2023. Orbit Discovery and Evergreen Discovery collaborate to discover peptides for targeting radiopharmaceuticals. News-Medical, viewed 15 July 2024, https://www.news-medical.net/news/20230403/Orbit-Discovery-and-Evergreen-Discovery-collaborate-to-discover-peptides-for-targeting-radiopharmaceuticals.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.